Gene-Disorder Association · Article
Gene
FLT3 Fms Related Receptor Tyrosine Kinase 3
×
First reported
1996
Supporting publications
28
Manually curated Approved treatment annotated
Association Review
In brief The association between FLT3 (Fms Related Receptor Tyrosine Kinase 3) and Leukemia, Acute Lymphoblastic is well established and manually curated, with its 2 contributing sources — 1 of them expert-curated — recording pathogenic variants.
Sources
2
Clinical variants
3
Symptoms
5
Compounds
9
Trials
461 of 4,741 via FLT3 compounds
Publications
28
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access 02
Provenance
Evidence and sources 2 sources
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access 3 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access 04
Leukemia, Acute Lymphoblastic
The disorder 21 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access 05
Phenotype
Clinical features 1 clinical feature
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access 06
ClinVar and variant evidence
Genetic basis 3 clinical variants
ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.
Request access 07
Mechanism overlap
Shared mechanisms Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
Request access 08
Interventions
Therapeutics 9 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access 09
Human studies
Clinical trials 4,741 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access 28 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access 11
Provenance
References & sources 17 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access 
